

Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis

Submission date 11/06/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 12/06/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 29/09/2022	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://www.medscinet.net/TACIT/patientinfodocs/Summary%20PIS%20Version%201%20%2820.12.07%29.pdf>

Study website

<http://www.tacit.org.uk>

Contact information

Type(s)

Scientific

Contact name

Prof David L Scott

Contact details

Department of Academic Rheumatology
King's College London
Weston Education Centre
Cutcombe Road
Denmark Hill
London
United Kingdom
SE5 9RJ
+44 (0)20 7848 5215
david.l.scott@kcl.ac.uk

Additional identifiers

EudraCT/CTIS number

2007-001190-28

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

HTA 06/303/84; KCL (Rheum) TACIT Version 1 (26/01/07)

Study information

Scientific Title

Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis

Acronym

TACIT

Study objectives

Active Rheumatoid Arthritis (RA) patients, who meet the National Institute for Clinical Excellence (NICE) criteria for treatment with Tumour Necrosis Factor (TNF) inhibitors, will gain equivalent benefit from intensive combination therapy (two or more Disease Modifying Anti-Rheumatic Drugs [DMARDs] and steroids) at substantially less expense and without increased toxicity.

More details can be found at: <http://www.nets.nihr.ac.uk/projects/hta/0630384>

Protocol can be found at: http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0003/51339/PRO-06-303-84.pdf

Ethics approval required

Old ethics approval format

Ethics approval(s)

Research ethics committee of the UCLH A, 20/04/2007, ref: 07/Q0505/57

Study design

Two-arm pragmatic 12-month randomised controlled multi-centred trial using open-label treatments

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

<http://www.medscinet.net/tacit/patientinfo.aspx?id=1>

Health condition(s) or problem(s) studied

Rheumatoid arthritis

Interventions

There will be two treatment algorithms:

1. For TNF inhibitors, and
2. For combination DMARDs

Treatments will be individualised and will depend on patients' responses.

TNF inhibitors:

All three licensed agents - adalimumab, etanercept, and infliximab - will be allowed at standard doses (British National Formulary). The choice of TNF inhibitor will reflect patient's preferences and local circumstances. Methotrexate will also be given to maximise efficacy and (in the case of infliximab) reduce anti-chimeric antibodies. Any patient intolerant to methotrexate may take another DMARD.

Combination DMARDs:

DMARDs from the following list will be used: methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, ciclosporin and gold injections (sodium aurothiomalate) in combinations with proven efficacy over DMARD monotherapy in Randomised Controlled trials (RCTs). For example:

1. Triple therapy with methotrexate (methotrexate-sulfasalazine-hydroxychloroquine)
2. Other methotrexate combinations (methotrexate-ciclosporin, methotrexate-leflunomide and methotrexate-gold)
3. One sulfasalazine combination (sulfasalazine-leflunomide)

Additional monthly steroids (intramuscular [IM] depomedrone [120 mg stat] or equivalent) will also be used if needed.

The duration of treatment is one year and patients are followed for only this year.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Adalimumab, etanercept, infliximab, methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, ciclosporin and gold injections (sodium aurothiomalate)

Primary outcome measure

Heath Assessment Questionnaire (HAQ).

Primary and secondary outcomes will be measured at baseline (month 0), 6 months and 12 months.

Secondary outcome measures

1. Joint damage
2. Quality of life
3. Disease activity
4. Withdrawal rates
5. Adverse effects
6. Economic evaluation:
 - 6.1. Societal costs
 - 6.2. Cost-effectiveness
 - 6.3. Cost-utility

Primary and secondary outcomes will be measured at baseline (month 0), 6 months and 12 months. Patients will be asked to attend monthly for blood monitoring and will be asked a short questionnaire regarding concomitant medication, any tests outside routine monitoring and adverse events within the last month.

Overall study start date

01/04/2007

Completion date

31/03/2010

Eligibility

Key inclusion criteria

1. Males and females aged over 18 years
2. Established RA by the criteria of the American College of Rheumatology
3. Disease duration of at least 12 months
4. Meet NICE criteria for being prescribed TNF inhibitors:
 - 4.1. Disease Activity Score (DAS) over 5.1
 - 4.2. Failure to respond to two DMARDs including methotrexate
 - 4.3. No contra-indications to TNF inhibitors (including possibility of pregnancy)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Key exclusion criteria

1. Unable or unwilling to give informed consent
2. Failure of, or contra-indications to, all proposed DMARD combinations (including possibility of pregnancy)
3. Serious inter-current illness
4. Patients on high dose steroids (in excess of 10 mg prednisolone or equivalent per day at trial entry)

Date of first enrolment

01/04/2007

Date of final enrolment

31/03/2010

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

King's College London

London

United Kingdom

SE5 9RJ

Sponsor information**Organisation**

King's College London (UK)

Sponsor details

Strand

London

England

United Kingdom

WC2R 2LS

+44 (0)20 7836 5454

ceu@kcl.ac.uk

Sponsor type

University/education

Website

http://www.kcl.ac.uk

ROR

https://ror.org/0220mzb33

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan**

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2014		Yes	No
Results article	results	13/03/2015		Yes	No

Other publications	secondary analysis	26/08/2016		Yes	No
Results article	cost-effectiveness results	01/03/2020	13/07/2020	Yes	No
Results article	Characterization of missing data patterns and mechanisms	17/09/2022	29/09/2022	Yes	No